Peroxisomal Acyl-CoA Oxidase Deficiency Overview
Learn About Peroxisomal Acyl-CoA Oxidase Deficiency
Peroxisomal acyl-CoA oxidase deficiency is a disorder that causes deterioration of nervous system functions (neurodegeneration) beginning in infancy. Newborns with peroxisomal acyl-CoA oxidase deficiency have weak muscle tone (hypotonia) and seizures. They may have unusual facial features, including widely spaced eyes (hypertelorism), a low nasal bridge, and low-set ears. Extra fingers or toes (polydactyly) or an enlarged liver (hepatomegaly) also occur in some affected individuals.
Peroxisomal acyl-CoA oxidase deficiency is caused by mutations in the ACOX1 gene, which provides instructions for making an enzyme called peroxisomal straight-chain acyl-CoA oxidase. This enzyme is found in sac-like cell structures (organelles) called peroxisomes, which contain a variety of enzymes that break down many different substances. The peroxisomal straight-chain acyl-CoA oxidase enzyme plays a role in the breakdown of certain fat molecules called very long-chain fatty acids (VLCFAs). Specifically, it is involved in the first step of a process called the peroxisomal fatty acid beta-oxidation pathway. This process shortens the VLCFA molecules by two carbon atoms at a time until the VLCFAs are converted to a molecule called acetyl-CoA, which is transported out of the peroxisomes for reuse by the cell.
Peroxisomal acyl-CoA oxidase deficiency is a rare disorder. Its prevalence is unknown. Only a few dozen cases have been described in the medical literature.
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
UPMC Heart And Vascular Institute
Santosh Pandit, MD, specializes in cardiology and is board-certified by the American Board of Internal Medicine, the National Board of Echocardiography, and the Certification Board of Nuclear Cardiology. He practices at UPMC Heart and Vascular Institute and is affiliated with UPMC Passavant. Dr. Pandit received his medical degree from Dr. Shankarrao Chavan Government Medical College in Nanded, India and completed his residency at the University of Pittsburgh School of Medicine, followed by a fellowship at Deborah Heart and Lung Center. Dr. Pandit is rated as an Advanced provider by MediFind in the treatment of Peroxisomal Acyl-CoA Oxidase Deficiency. His top areas of expertise are Heart Failure with Preserved Ejection Fraction (HFpEF), Atrial Fibrillation, Aortic Valve Stenosis, and Hypertension.
Pierre Dalumpines is a primary care provider, practicing in Family Medicine in Gig Harbor, Washington. Dr. Dalumpines is rated as an Experienced provider by MediFind in the treatment of Peroxisomal Acyl-CoA Oxidase Deficiency. His top areas of expertise are Insomnia, Obesity in Children, High Cholesterol, and Opisthotonos. Dr. Dalumpines is currently accepting new patients.
Nobuyuki Shimozawa practices in Gifu-shi, Japan. Mr. Shimozawa is rated as a Distinguished expert by MediFind in the treatment of Peroxisomal Acyl-CoA Oxidase Deficiency. His top areas of expertise are Zellweger Syndrome, Adrenoleukodystrophy (ALD), Addison's Disease, Peroxisomal Acyl-CoA Oxidase Deficiency, and Bone Marrow Transplant.
Summary: This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP).
Summary: The Peroxisome Biogenesis Disorders (PBD) are a group of inherited disorders due to defects in peroxisome assembly causing complex developmental and metabolic sequelae. In spite of advancements in peroxisome biology, the pathophysiology remains unknown, the spectrum of phenotypes poorly characterized and the natural history not yet systematically reported. Our aims are to further define this popul...
Published Date: February 01, 2018
Published By: National Institutes of Health
